Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide

3022 Background: The most common adverse events associated with ipilimumab, an anti cytotoxic T-lymphocyte antigen-4 drug for the treatment of advanced melanoma, are immune in nature and primarily gastrointestinal (GI). These immune-related adverse events (irAEs) are likely due to ipilimumab-mediated activation of the immune system. Immune-derived biomarkers that may be associated with response/GI irAEs were explored. Methods: In this...